Co-existing coronary artery disease affects 38.0% to 74.9% of patients undergoing transcutaneous aortic valve implantation, but the optimal timing and necessity of revascularization remain unresolved.
Does percutaneous coronary intervention improve outcomes in patients with severe aortic stenosis and co-existing coronary artery disease planned for transcatheter aortic valve implantation?
This review emphasizes the current lack of definitive evidence regarding the assessment and revascularization of coronary artery disease prior to TAVI, underscoring the need for results from ongoing randomized trials.
Transcutaneous aortic valve implantation (TAVI) has led to a paradigm shift in the treatment of severe aortic stenosis (AS) in the elderly and is expanding to still younger and lower-risk patients with severe AS as an alternative to surgical aortic valve replacement (SAVR). While the role of coronary artery bypass grafting with SAVR is well-documented, the analog of percutaneous coronary intervention with TAVI is less so. The aim of this review is to provide an overview of the important challenges in treating severe AS and co-existing coronary artery disease in patients planned for TAVI.
Sabbah et al. (Fri,) conducted a review in Severe aortic stenosis and co-existing coronary artery disease. Percutaneous coronary intervention (PCI) and Transcutaneous aortic valve implantation (TAVI) vs. TAVI alone or Surgical aortic valve replacement (SAVR) with Coronary artery bypass grafting (CABG) was evaluated. Co-existing coronary artery disease affects 38.0% to 74.9% of patients undergoing transcutaneous aortic valve implantation, but the optimal timing and necessity of revascularization remain unresolved.